Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN), a cancer immunotherapy company based in Israel, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 12:00 pm ET. This virtual event will feature a live webcast available on Compugen's Investor Relations website. The company is focused on innovative predictive target discovery and developing therapeutics, including lead candidate COM701, an anti-PVRIG antibody, and COM902 targeting TIGIT. Compugen's shares are traded on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.

HOLON, Israel, Feb. 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference (virtual), on Wednesday, February 16, 2022 at 12:00 pm ET.

A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.

About Compugen 

Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 studies in dual, and triple combinations. COM902, Compugen's second fully owned clinical antibody targeting TIGIT, for the treatment of solid and hematological tumors, is undergoing Phase 1 studies as a single agent and in dual combination. Partnered programs include bapotulimab, a therapeutic antibody in Phase 1 development targeting ILDR2 licensed to Bayer under a research and discovery collaboration and license agreement, and AZD2936, a TIGIT/PD-1 bispecific in Phase 1 development derived from COM902 through a license agreement with AstraZeneca for the development of bispecific and multi-specific antibodies. Compugen's therapeutic pipeline of early-stage immuno-oncology programs includes myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com. 

Investor Relations contact:
Yvonne Naughton, PhD
Head of Investor Relations and Corporate Communications Compugen Ltd.
Email: ir@cgen.com  
Tel: +1 (628) 241-0071

View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-301478503.html

SOURCE Compugen Ltd.

FAQ

When is Compugen's presentation at the SVB Leerink Global Healthcare Conference?

Compugen will present on February 16, 2022, at 12:00 pm ET.

Where can I watch the Compugen presentation live?

The presentation will be available as a live webcast on Compugen's Investor Relations website.

What are Compugen's lead product candidates?

Compugen's lead candidates include COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT.

What is the stock symbol for Compugen?

Compugen's stock is listed under the ticker symbol CGEN.

What type of company is Compugen?

Compugen is a clinical-stage company focused on cancer immunotherapy and predictive target discovery.